Denosumab (DMAB) Discontinuation And Switching In Glucocorticoid-Induced Osteoporosis (GIOP): A Pilot Study
Status:
Recruiting
Trial end date:
2024-08-31
Target enrollment:
Participant gender:
Summary
Investigators will test the hypothesis that an increase in bone turnover markers (e.g.
carboxy-terminal collagen crosslinks (CTX) and P1NP) in patients currently taking chronic
glucocorticoids will be attenuated more in those who switch from denosumab to "late"
zoledronic acid (9 months after last denosumab dose) compared to participants randomized to
"early" zoledronic acid (6 months after last denosumab dose) or weekly alendronate (6 months
after last denosumab dose).